全球慢性心臟衰竭市場：按地區和國家分析和預測（2025 年至 2035 年）

Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

出版日期: 2025年06月30日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

慢性心臟衰竭市場的主要成長要素之一是心血管疾病盛行率的上升。

隨著高血壓、冠狀動脈疾病、糖尿病和肥胖等心血管疾病變得越來越普遍，慢性心臟衰竭的發生率也在增加，對有效治療方法的需求也增加。此外，人口老化也對市場擴張做出了重大貢獻。由於老年人心臟衰竭的風險更高，人口老化也對市場擴張做出了重大貢獻。診斷技術和治療方法的進步也使得人們能夠更早發現並更有效地管理慢性心臟衰竭，進一步推動了市場成長。 SGLT2抑制劑和植入式設備等創新新治療方法和醫療設備設備的開發正在改善患者的預後，加速了對治療的需求。隨著越來越多的患者被診斷出患有心臟衰竭並且壽命延長，對更好的治療和管理方法的需求也在不斷擴大，從而推動了慢性心臟衰竭市場的成長。

儘管市場正在成長，但仍存在一些挑戰，阻礙其發展。其中一個主要挑戰是治療費用高。包括新藥研發、醫療設備和住院費用在內的先進治療方法往往很昂貴，導致一些患者難以獲得所需的治療。尤其是在醫療基礎設施薄弱的低收入國家和新興市場，這些高成本治療的可近性受到限制。

另一個重大挑戰是治療的複雜性。慢性心臟衰竭衰竭是一種多因素疾病，具有多種潛在病因，許多患者也患有糖尿病、高血壓和腎臟疾病等併發症。這使得採用一刀切的治療方法變得困難，需要結合藥物和非藥物療法進行多層面的管理。此外，由於疾病是慢性的，患者往往難以堅持複雜的治療方案，導致預後較差，再住院率較高。

此外，儘管新的藥物療法前景光明，但某些患者群體仍然缺乏有效的治療方法。尤其是射血分數保留型心臟衰竭衰竭(HFpEF) 患者，治療方法與射血分數降低型心臟衰竭(HFrEF) 患者相比有限，導致該領域存在大量未滿足的醫療需求。

最後，慢性心臟衰竭早期診斷不足和延誤診斷仍然是一項重大挑戰。許多患者直到症狀出現才意識到病情，而延遲診斷會導致預後不良和介入效果受限。儘管早期識別和管理慢性心臟衰竭至關重要，但在某些地區，由於缺乏認知和篩檢系統，診斷常常被延誤。

本報告調查了全球慢性心臟衰竭市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

主要策略和發展
- M&A
- 協同活動
- 業務擴展和資金籌措
- 產品發布和核准
- 其他活動
公司簡介
- AstraZeneca
- Bristol Myers Squibb
- Cytokinetics
- Bayer AG
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson
- Amgen Inc.
- Takeda Pharmaceutical Company
- AbbVie Inc.
- Sanofi

第4章調查方法

簡介目錄圖表

Product Code: BHL3066SA

Global Chronic Heart Failure Market, Analysis and Forecast: 2025-2035

Chronic heart failure is a long-term condition where the heart is unable to pump blood efficiently to meet the body's needs for oxygen and nutrients. This inability to pump effectively leads to fluid buildup in the lungs, abdomen, and legs, causing symptoms such as shortness of breath, fatigue, swelling, and exercise intolerance. chronic heart failure can develop because of underlying conditions such as coronary artery disease, hypertension, diabetes, or previous heart attacks. The condition can be classified into two main types based on heart function: Heart Failure with Reduced Ejection Fraction (HFrEF), where the heart's pumping ability is weakened, and Heart Failure with Preserved Ejection Fraction (HFpEF), where the heart muscle becomes stiff and doesn't fill properly. Chronic heart failure is progressive, meaning it worsens over time, and requires ongoing management with medications, lifestyle changes, and sometimes medical devices or surgeries to improve symptoms and quality of life.

One of the key drivers of the chronic heart failure market is the rising prevalence of cardiovascular diseases such as hypertension, coronary artery disease, diabetes, and obesity. As these conditions become more widespread, the incidence of chronic heart failure increases, driving demand for effective treatments. The aging population is also contributing significantly to the growing market, as older individuals are at higher risk for developing heart failure. Additionally, advancements in diagnostic technologies and treatment options are allowing for earlier detection and more effective management of chronic heart failure, further boosting the market. The development of new, innovative therapies and medical devices, such as SGLT2 inhibitors and implantable devices, is improving patient outcomes, which in turn is accelerating the demand for chronic heart failure treatments. As more individuals are diagnosed and live longer with heart failure, the need for better treatment and management options continues to expand, propelling chronic heart failure market growth.

Despite the growth of the chronic heart failure market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment. The development of advanced therapies, including new drug classes, medical devices, and hospitalization costs, can be prohibitively expensive, making it difficult for some patients to access the necessary care. This is especially true in low-income and emerging markets, where healthcare infrastructure may be limited.

Another significant challenge is the complexity of treatment. chronic heart failure is a multifactorial disease with various underlying causes, and patients often present with comorbidities such as diabetes, hypertension, and kidney disease. This makes it difficult to develop a one-size-fits-all treatment approach, and managing the disease often requires a combination of pharmacological and non-pharmacological interventions. Moreover, the long-term nature of the condition means that adherence to complex treatment regimens is often low, leading to poor outcomes and increased hospitalizations.

Additionally, while new drug therapies have shown promise, there is still a lack of effective treatments for certain subsets of patients, particularly those with heart failure with preserved ejection fraction (HFpEF). This group of patients has limited treatment options compared to those with heart failure with reduced ejection fraction (HFrEF), leaving a significant unmet need in the chronic heart failure market.

Finally, the underdiagnosis and delayed diagnosis of chronic heart failure in its early stages also poses a major challenge. Many patients may not experience noticeable symptoms until the disease is advanced, leading to poor prognosis and reduced effectiveness of interventions. Early identification and management of chronic heart failure are critical, but the lack of awareness and insufficient screening programs in some regions contribute to late-stage diagnoses.

These challenges underscore the need for continued innovation, improved accessibility, and early detection strategies to overcome the barriers to effective chronic heart failure management.

The global chronic heart failure market is highly competitive, with several key players driving innovation and market growth. Leading companies such as AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer AG, Eli Lilly and Company, and scPharmaceuticals are at the forefront of the market, each contributing through innovative therapies, medical devices, and treatments. These companies are focusing on expanding the availability of advanced drug therapies such as SGLT2 inhibitors (e.g., dapagliflozin), neprilysin inhibitors (e.g., sacubitril/valsartan), and ARBs, all of which are transforming the treatment of heart failure. Additionally, advancements in medical devices for heart failure management, such as implantable defibrillators and ventricular assist devices, are contributing to better patient outcomes. As these companies continue to invest in research and development, the competition within the chronic heart failure market is driving further innovation, ultimately leading to more effective treatments, improved patient quality of life, and reduced hospitalizations.

Chronic Heart Failure Market Segmentation:

Chronic Heart Failure Segmentation 1: by Region

North America
Europe
Asia-Pacific

The global chronic heart failure market is experiencing significant transformation driven by several emerging trends. There is a growing emphasis on personalized medicine, with advancements in genomic testing and biomarker identification allowing for more tailored treatments that are specific to the patient's unique condition, improving the effectiveness of therapies. Additionally, innovative drug therapies such as SGLT2 inhibitors, neprilysin inhibitors, and ARBs are gaining prominence for their ability to not only improve heart function but also reduce hospitalizations and enhance survival rates, particularly in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Another major trend is the increasing integration of digital health technologies such as wearables, remote monitoring devices, and telemedicine, which enable continuous tracking of patient health and more proactive management of chronic heart failure symptoms. These technologies help detect early signs of deterioration, prevent hospital readmissions, and optimize treatment regimens. Furthermore, the growing focus on patient-centred care is reshaping the chronic heart failure market by promoting a holistic approach to chronic heart failure management, combining pharmacological treatments with lifestyle modifications, rehabilitation, and psychological support to improve the quality of life for patients.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Heart Failure Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology Analysis
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Chronic Heart Failure Market (Region), ($Billion), 2023-2035

2.1 North America
- 2.1.1 Key Findings
- 2.1.2 Market Dynamics
- 2.1.3 Market Sizing and Forecast
  - 2.1.3.1 North America Chronic Heart Failure Market, by Country
    - 2.1.3.1.1 U.S.
2.2 Europe
- 2.2.1 Key Findings
- 2.2.2 Market Dynamics
- 2.2.3 Market Sizing and Forecast
  - 2.2.3.1 Europe Chronic Heart Failure Market, by Country
    - 2.2.3.1.1 Germany
    - 2.2.3.1.2 U.K.
    - 2.2.3.1.3 France
    - 2.2.3.1.4 Italy
2.3 Asia Pacific
- 2.3.1 Key Findings
- 2.3.2 Market Dynamics
- 2.3.3 Market Sizing and Forecast
  - 2.3.3.1 Asia Pacific Chronic Heart Failure Market, by Country
    - 2.3.3.1.1 China
    - 2.3.3.1.2 Japan

3. Global Chronic Heart Failure Market: Competitive Landscape and Company Profiles

3.1 Key Strategies and Development
- 3.1.1 Mergers and Acquisitions
- 3.1.2 Synergistic Activities
- 3.1.3 Business Expansions and Funding
- 3.1.4 Product Launches and Approvals
- 3.1.5 Other Activities
3.2 Company Profiles
- 3.2.1 AstraZeneca
  - 3.2.1.1 Overview
  - 3.2.1.2 Top Products / Product Portfolio
  - 3.2.1.3 Top Competitors
  - 3.2.1.4 Target Customers/End-Users
  - 3.2.1.5 Key Personnel
  - 3.2.1.6 Analyst View
- 3.2.2 Bristol Myers Squibb
  - 3.2.2.1 Overview
  - 3.2.2.2 Top Products / Product Portfolio
  - 3.2.2.3 Top Competitors
  - 3.2.2.4 Target Customers/End-Users
  - 3.2.2.5 Key Personnel
  - 3.2.2.6 Analyst View
- 3.2.3 Cytokinetics
  - 3.2.3.1 Overview
  - 3.2.3.2 Top Products / Product Portfolio
  - 3.2.3.3 Top Competitors
  - 3.2.3.4 Target Customers/End-Users
  - 3.2.3.5 Key Personnel
  - 3.2.3.6 Analyst View
- 3.2.4 Bayer AG
  - 3.2.4.1 Overview
  - 3.2.4.2 Top Products / Product Portfolio
  - 3.2.4.3 Top Competitors
  - 3.2.4.4 Target Customers/End-Users
  - 3.2.4.5 Key Personnel
  - 3.2.4.6 Analyst View
- 3.2.5 Eli Lilly and Company
  - 3.2.5.1 Overview
  - 3.2.5.2 Top Products / Product Portfolio
  - 3.2.5.3 Top Competitors
  - 3.2.5.4 Target Customers/End-Users
  - 3.2.5.5 Key Personnel
  - 3.2.5.6 Analyst View
- 3.2.6 Novartis AG
  - 3.2.6.1 Overview
  - 3.2.6.2 Top Products / Product Portfolio
  - 3.2.6.3 Top Competitors
  - 3.2.6.4 Target Customers/End-Users
  - 3.2.6.5 Key Personnel
- 3.2.7 Pfizer Inc.
  - 3.2.7.1 Overview
  - 3.2.7.2 Top Products / Product Portfolio
  - 3.2.7.3 Top Competitors
  - 3.2.7.4 Target Customers/End-Users
  - 3.2.7.5 Key Personnel
  - 3.2.7.6 Analyst View
- 3.2.8 Johnson & Johnson
  - 3.2.8.1 Overview
  - 3.2.8.2 Top Products / Product Portfolio
  - 3.2.8.3 Top Competitors
  - 3.2.8.4 Target Customers/End-Users
  - 3.2.8.5 Key Personnel
  - 3.2.8.6 Analyst View
- 3.2.9 Amgen Inc.
  - 3.2.9.1 Overview
  - 3.2.9.2 Top Products / Product Portfolio
  - 3.2.9.3 Top Competitors
  - 3.2.9.4 Target Customers/End-Users
  - 3.2.9.5 Key Personnel
  - 3.2.9.6 Analyst View
- 3.2.10 Takeda Pharmaceutical Company
  - 3.2.10.1 Overview
  - 3.2.10.2 Top Products / Product Portfolio
  - 3.2.10.3 Top Competitors
  - 3.2.10.4 Target Customers/End-Users
  - 3.2.10.5 Key Personnel
  - 3.2.10.6 Analyst View
- 3.2.11 AbbVie Inc.
  - 3.2.11.1 Overview
  - 3.2.11.2 Top Products / Product Portfolio
  - 3.2.11.3 Top Competitors
  - 3.2.11.4 Target Customers/End-Users
  - 3.2.11.5 Key Personnel
  - 3.2.11.6 Analyst View
- 3.2.12 Sanofi
  - 3.2.12.1 Overview
  - 3.2.12.2 Top Products / Product Portfolio
  - 3.2.12.3 Top Competitors
  - 3.2.12.4 Target Customers/End-Users
  - 3.2.12.5 Key Personnel
  - 3.2.12.6 Analyst View